Policy Summary
Medical review policy
Medical and regulatory statements are checked against FDA guidance, prescribing information, clinical trial sources, and provider documentation. We do not invent named medical reviewers.
Editorial team and clinical review
Affordable Compounded Tirzepatide is independent but may earn referral compensation from listed companies on this website. Compensation may affect CTA placement, but pages must still use published pricing, visible disclosures, and source-based safety language.
Editorial and review structure. Content on Affordable Compounded Tirzepatide is produced and maintained by the site's editorial team. Pricing, pharmacy, and safety information is checked against primary sources, including FDA compounding and GLP-1 guidance, state pharmacy board standards, USP sterile-compounding standards, and the prescribing information and clinical-trial data for the relevant brand-name products. We do not currently publish a named individual medical reviewer; where a page involves clinical or dosing information, it is reviewed by the editorial team against these primary sources rather than attributed to a named clinician. If and when a credentialed medical reviewer is added, that person will be named here with verifiable credentials.
Key standards
Medical and regulatory statements are checked against FDA guidance, prescribing information, clinical trial sources, and provider documentation. We do not invent named medical reviewers.
Compounded tirzepatide and compounded semaglutide are not FDA-approved as finished drugs. They may be prescribed only when a licensed provider determines they are clinically appropriate and legally permissible for an individual patient. Brand-name medications such as Mounjaro, Zepbound, Ozempic, and Wegovy are FDA-approved products and should not be treated as identical to compounded medications.
Frequently asked questions
Can I request a correction?
Yes. Use the contact page or correction policy to request a source or pricing correction.
Is this medical advice?
No. The site is informational only and does not replace licensed medical advice.
Sources
- FDA GLP-1 compounding policy clarification (Regulator)
- FDA Compounding and the FDA: Questions and Answers (Regulator)
- FDA 503B bulks list proposal for GLP-1 drugs (Regulator)
- Zepbound prescribing information (Label)
- Wegovy prescribing information (Label)
- NexLife tirzepatide pricing page (Provider pricing)
- NexLife FAQ pricing page (Provider pricing)
- NexLife semaglutide pricing page (Provider pricing)